Homology(FIXX) - 2025 Q4 - Annual Results

Clinical Trials - Q32 Bio completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, increasing the trial size to 33 patients, with topline data readout expected in mid-2026[1] - The company expects to report 36-week topline results from the SIGNAL-AA Part B trial in mid-2026, with emerging signs of clinical activity observed[4] Financial Performance - Q32 Bio reported a net income of $57.7 million for Q4 2025, compared to a net loss of $14.2 million in Q4 2024[7] - The company recognized non-cash collaboration revenue associated with an amended agreement with Amgen, contributing to the net income for the quarter[7] Funding and Cash Position - The company completed a $10.5 million registered direct offering in February 2026, issuing 1,666,679 shares at an offering price of $3.90 per share[4] - Cash and cash equivalents were $48.3 million as of December 31, 2025, expected to fund operations into Q4 2027[7] Expenses - Research and development expenses decreased to $3.3 million for Q4 2025 from $10.5 million in Q4 2024, and to $19.2 million for the full year 2025 from $48.1 million in 2024[7] - General and administrative expenses for Q4 2025 were $4.5 million, up from $4.0 million in Q4 2024, while full year expenses decreased to $17.7 million from $18.0 million[7] Asset and Equity Changes - Total assets decreased from $92,332 million in 2024 to $61,776 million in 2025, representing a decline of approximately 33%[17] - Total stockholders' equity increased from $5,675 million in 2024 to $42,014 million in 2025, reflecting a substantial growth of approximately 640%[17] Liabilities and Debt - Accounts payable and accrued expenses decreased from $10,468 million in 2024 to $5,111 million in 2025, a reduction of about 51%[17] - Venture debt reduced from $12,653 million in 2024 to $9,708 million in 2025, indicating a decrease of approximately 23.1%[17] - Lease liability, net of current portion, decreased from $5,636 million in 2024 to $4,943 million in 2025, a decline of about 12.3%[17] - CVR liability was eliminated in 2025, down from $2,900 million in 2024[17] Other Financial Metrics - Cash and cash equivalents dropped significantly from $77,965 million in 2024 to $48,297 million in 2025, a decrease of about 38.3%[17] - Other assets increased from $5,398 million in 2024 to $7,732 million in 2025, representing a growth of approximately 43.2%[17] - The company reported no equity investment in 2025, down from $2,600 million in 2024[17] - Restricted cash and restricted cash equivalents remained unchanged at $647 million for both years[17] - Q32 Bio sold the Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments and potential future milestone payments totaling up to $592 million[4] - Q32 Bio terminated all remaining obligations to Amgen, eliminating potential milestone payments owed under the previous agreement[4]